4 kg loss in first month and rising to 11.6 kg after 1 year
The weight loss medication Xenical helps patients achieve rapid and sustained weight loss according to the results of a new study designed to reflect real world usage of Xenical in clinical practice. 1
The 12 month study of 430 overweight men and women (BMI of 30-43 kg/m2), was designed to assess the effectiveness of Xenical in patients who are responsive to treatment. Patients who achieved 5 per cent (approximately 5kg) weight loss after 3 months and maintained this after a further 3 months of Xenical treatment, were followed for one year. During this time weight loss and other health improvements, such as reductions in blood pressure, were assessed. The results suggest that the efficacy of Xenical in a real-life clinical practice setting is even greater than that demonstrated previously in clinical trials:
The greatest weight loss was seen in the first four weeks of treatment, with an average weight loss of 4.1 kg
Three out of four people achieved 5 per cent weight loss by month three, losing an average of 8kg
Continue Reading Below ↓↓↓
By month 6, 92 per cent of these people had maintained at least 5 per cent weight loss, with an average weight loss of 10.9kg.
The average weight loss after one year was 11.6 kg. One in two patients in the study lost more than 10 per cent of their initial weight, and over 8 in ten people lost more than 5 per cent � an amount of weight loss shown to clinically improve the health and well-being of overweight people 2
Commenting on the results, lead study investigator Professor Hermann Toplak from the Karl-Franzens-Universit�t, Graz, Austria said �These results demonstrate the significant benefits of rapid and continuous weight loss with Xenical in a clinical practice setting. Patients who respond rapidly to treatment continue with treatment and achieve long-term success.�
Results also demonstrated significant health gains associated with weight loss with Xenical. Specifically, people treated with Xenical achieved improvements in:
Waist circumference: An average reduction of 10.8 cm was achieved after one year. Excess fat around the waist is associated with insulin resistance, high blood sugar, high cholesterol levels and high blood pressure
Blood pressure (bp): In patients with hypertension, mean systolic and diastolic blood pressure were reduced by 18.1mmHg and 9.9mmHg respectively
Cholesterol: The lipid profile of patients was markedly improved: mean LDL-cholesterol (�bad� cholesterol) levels were reduced by 10.7 per cent and mean total cholesterol levels by 6.8 per cent.
The reductions in blood pressure are a key finding as the number of overweight people with hypertension is almost three times higher than the number of adults with a healthy weight. 3 Xenical is the only prescription weight-loss medication, which can be used in patients with hypertension or uncontrolled hypertension.4
Xenical�s mode of action is unique. Unlike appetite suppressants, which have a history of withdrawals because of safety concerns, Xenical does not act on the central nervous system. As a result of Xenical�s non-systemic mode of action, it has a safety and tolerability profile, which makes it appropriate for use in a wide range of people. This is particularly important within the area of overweight/obesity, where a significant number of people suffer from, or are at risk of cardiovascular disease.
References:
Continue Reading Below ↓↓↓
- Toplak H. Oral Presentation at Seville, Roche Event, 31 May � 1 June 2002
- Goldstein DJ. International Journal of Obesity (1992). 16:397-415
- Pi-Sunyer FX. �Medical Hazards of Obesity.� Ann Intern Med (1993). 119: 655-660.
- Yanovski S et al. Obesity. NEJM 2002; 346 (8): 591-602
Source: Shire Health International
